Stockreport
Gilead +12% on coronavirus treatment testing [Seeking Alpha]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
On the Move | Healthcare Gilead +12% on coronavirus treatment testing Feb. 3, 2020 6:06 AM ET Gilead Sciences, Inc. (GILD) Yoel Minkoff Shares of Gilead Sciences (NASDAQ: up 12% formalizing "Gilead is working with health authorities in China to establish a randomized, controlled trial to determine whether remdesivir can safely and effectively be used to treat 2019-nCoV," the company said in a statement. "While there are no antiviral data for remdesivir that show activity against 2019-nCoV at this time, available data in other coronaviruses give us hope." Trials for the drug will be conducted in Wuhan, the central Chinese city that is ground zero for the current outbreak. See all stocks on the move » Now read: December Portfolio Update »
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- Gilead Sciences Earnings Preview: What to Expect [Yahoo! Finance][Yahoo! Finance]
- Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales [Yahoo! Finance][Yahoo! Finance]
- Gilead Sciences (NASDAQ:GILD) had its price target lowered by analysts at Royal Bank Of Canada from $105.00 to $100.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $110.00 to $115.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Hopping Mad Over Drug Company Product Hopping [Forbes][Forbes]
- More
GILD
SEC Filings
SEC Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/15/26 - Form 144
- GILD's page on the SEC website
- More